NCT03732820: A reported trial by AstraZeneca
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT03732820 |
---|---|
Title | A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study) |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Oct. 31, 2018 |
Completion date | July 30, 2021 |
Required reporting date | July 30, 2022, midnight |
Actual reporting date | July 29, 2022 |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |